Comparative Pharmacology
Head-to-head clinical analysis: SULFAIR FORTE versus SULFALOID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SULFAIR FORTE versus SULFALOID.
SULFAIR FORTE vs SULFALOID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Folate antagonist; inhibits dihydropteroate synthetase in bacterial folate synthesis pathway.
Sulfaloid is a sulfonamide antibiotic that inhibits bacterial dihydropteroate synthase, blocking folate synthesis and thereby nucleic acid production in susceptible bacteria.
1-2 tablets (sulfamethoxazole 400 mg/trimethoprim 80 mg per tablet) orally every 12 hours.
500 mg orally every 12 hours for 7-10 days.
None Documented
None Documented
Approximately 10-12 hours in patients with normal renal function; prolonged in renal impairment (up to 20-30 hours), necessitating dose adjustment.
Terminal elimination half-life: 6-8 hours in adults with normal renal function (ClCr >90 mL/min); prolonged to 12-20 hours in moderate renal impairment (ClCr 30-50 mL/min) and >30 hours in severe renal impairment (ClCr <30 mL/min).
Primarily renal excretion of unchanged drug (approx. 70-80%) and glucuronide conjugates; biliary excretion accounts for less than 20%; fecal elimination minimal.
Renal: 70% (unchanged via glomerular filtration and tubular secretion); Biliary/fecal: 20% (conjugated metabolites); 10% metabolized in liver to inactive acetylated derivatives.
Category C
Category C
Antibiotic (Sulfonamide)
Antibiotic (Sulfonamide)